DBV

DBV Technologies is a French biotech company, whose lead product is a patch for the treatment of peanut allergy

DBV raised additional funding to finance its development strategy, while the transaction also allowed long-term holders to monetize part of their stakes.
Kempen & Co acted as Joint Bookrunner and placed 80% of the shares with US investors.